Pyxis Oncology, Inc. Share Price & Technical Analysis
PYXS · $1.96 (+1.03%)
Healthcare / Biotechnology
$1.96
+1.03%
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic …
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
18% return in May, 0% avg return in past 3 year May month.
70% return in 2026, 77% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 25% | 7% | 7% | 13% | 18% | – | – | – | – | – | – | – | 70% |
| 25 | 0% | -20% | -17% | 10% | 9% | -8% | 0% | 18% | 69% | 64% | 49% | -78% | 95% |
| 24 | 111% | 68% | -34% | 2% | -16% | -13% | 18% | -3% | 0% | 0% | -44% | -20% | 70% |
| 23 | 14% | 44% | 82% | -33% | 7% | -19% | 0% | -12% | -9% | -15% | -6% | 13% | 65% |
| 22 | -15% | -36% | -34% | -37% | 0% | -4% | 13% | 0% | -20% | -5% | -21% | -19% | -179% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$159.65M
P/E ratio
—
52W high
$5.55
52W low
$0.97
Volume
10,28,727
Beta
1.43
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Pyxis Oncology, Inc. share price today?
- Pyxis Oncology, Inc. (PYXS) last traded around $1.96 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PYXS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PYXS. Download the app for real-time alerts.
- How can I analyze Pyxis Oncology, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.